James Rowe, PhD, University of Cambridge, Cambridge, UK, discusses the exciting prospects in progressive tauopathy research. Prof. Rowe expresses interest in the development of new treatments and suggests that a similar approach should be taken to cancer in which a combination of drugs is proven effective. Other areas of interest are the increasing use of biomarkers, PET and MRI scans to investigate living patients. Finally, Prof. Rowe describes how collaboration will increase the speed to results, but when discovering disease-modifying drugs, symptomatic relief should not be ignored. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).